A patient with a lymphoproliferative disorder developed bleeding associated with a prolonged bleeding time and a selective defect of platelet aggregation in response to ristocetin. The patient's purified IgG was shown to inhibit aggregation of washed normal platelets by ristocetin and von Willebrand factor (F VIII:vWF). By Western blotting, it was shown that antibody bound specifically to an antigen of M, 210,000 present on normal platelets but missing on platelets from patients with congenital BernardSoulier syndrome (BSS). Binding was effected by the F(ab)2 portion of the IgG, indicating the presence of an autoantibody rather than an immune complex. These results suggest that the 210,000-
Introduction
The Bernard-Soulier syndrome (BSS)' is a rare autosomal recessive bleeding disorder characterized by moderate to severe thrombocytopenia and abnormally large platelets that have diminished adhesion to the vascular subendothelium (1) . Ristocetin-induced binding of von Willebrand factor (F VIII:vWF) to these platelets has been shown to be reduced (2). The molecular basis for these functional abnormalities appears to be deficiency of glycoprotein lb (GP Ib), a major component of the platelet plasma membrane (3 also been shown to be deficient in membrane glycoproteins V (Mr 82,000) and IX (M, 22 ,000) (1) . The significance of these membrane defects is unclear, however.
The structure of GP lb appears to be complex. Unreduced GP lb has been shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to have a molecular weight of 170,000 when labeled with 3H after periodate treatment of platelet membranes (4) . In contrast, labeling of GP lb with "25I after neuraminidase treatment yields a polypeptide of M, 150,000 (5) . In addition, Nachman et al. (5) and Kunicki et al. (6) have identified a membrane glycoprotein that copurifies with GP lb when wheat germ lectin affinity chromatography is employed. This "structural analogue" of GP lb has a molecular weight of 210,000 by SDS-PAGE (5, 6 ). It has not been further charactenzed.
We describe a patient with lymphadenopathy and a polyclonal gammopathy of unknown etiology who developed excessive bleeding associated with a prolonged bleeding time and abnormal ristocetin-induced platelet aggregation. A circulating immunoglobulin G (IgG) that inhibited ristocetin-induced platelet aggregation was shown to bind specifically to the 210,000-Mr protein. Table I ). (10 ,uM) , collagen (0.26 mg/ml), gamma thrombin (2 Ag/ml), arachidonic acid (500 gg/ml), calcium ionophore A23 187 (13 ,g/ml), and ristocetin (1.5 and 3 mg/ml). Initial studies were carried out using the patient's platelet-rich plasma. Subsequent aggregation studies were performed on washed human platelets, using the following procedure. Utilizing a discontinuous 10-20% Stractan gradient and isopycnic centrifugation (13) 50 ,ul ofplatelets was electrophoresed in 5% SDS-polyacrylamide gels according to the method of Laemmli (14). The samples were then transferred to nitrocellulose by the method of Towbin et al. (15) at 30 V for 16 h. Blocking was performed using 5% gelatin in Tris-buffered saline (TBS) for 1 h at 370C, after which the nitrocellulose was incubated with test serum, IgG, or F(ab)2 diluted 1 100 in TBS-l% gelatin for 2 h. After washing in TBS, the samples were incubated with a 1:500 dilution of biotin-conjugated goat F(ab)2 anti-human immunoglobulin (Tago Inc., Burlingame, CA) for 1 h. After further washing in TBS, the nitrocellulose was incubated with avidin-conjugated peroxidase (Cappel Laboratories, Malvern, PA) diluted 1:500 in TBS 1% gelatin for I h. Color development was carried out using 4-chloronaphthol as substrate ( 16) . The nitrocellulose was then dried and photographed. High molecular weight standards (Bio-Rad Laboratories, Hayward, CA, and Pharmacia Fine Chemicals, Piscataway, NJ) were simultaneously electrophoresed and transferred with the samples. These were stained with 0.05% amido black and served as molecular weight markers for the blots.
Results
The results of coagulation studies and routine platelet aggregometry are shown in but decreased reactivity to ADP and collagen. Finally, heat-aggregated control IgG was also shown to bind to the Mr 210,000 antigen (lane C), suggesting the possibility of interaction with an F(c) receptor. However, the patient's F(ab)2 also bound to this antigen (lane D), indicating that an autoantibody rather than an immune complex was responsible for binding. The mechanism of ristocetin-induced platelet aggregation has been presumed to involve binding ofF VIII:vWF to the GP lb complex (17) . The effect of ristocetin is thought to be related to its net positive charge (18) . Because both the F VIII:vWF molecule and the platelet surface are electronegatively charged, they are mutually repulsive. Ristocetin interaction with the GP lb complex decreases the net negative charge on the platelet surface, allowing F VIII:vWF to bind (18) . Alteration of the charge on the F VIII:vWF molecule, such as in some forms of acquired von Willebrand disease (vWD) (17) , or lack of binding of F VIII:vWF to the absent GP lb complex, such as in BSS (19) , results in decreased ristocetin-induced platelet aggregation.
Our patient differs from reported cases of acquired vWD in several important respects. Although the bleeding history, bleeding time, and defective ristocetin-induced platelet aggregation are consistent with acquired vWD, all functional and immunologic components of the patient's F VIII complex are intact. In addition, the inhibitory effect of IgG on platelet aggregation and the demonstration of serum antibody binding to autologous platelets strongly suggest acquired platelet dysfunction. To our knowledge, this type of antibody-induced dysfunction in the presence of a normal platelet count has not previously been reported. Degos et al. (20) described a polytransfused BSS patient with alloantibody against a component of GP lb, but this antibody did not react with the patient's own platelets since they lacked the glycoprotein. Quinidine-dependent antiplatelet antibody appears to be directed against the GP lb complex (4, 6) , but this antibody generally results in accelerated platelet destruction and has not been shown to cause platelet dysfunction. Recently, Woods et al. (21) identified autoantibody to GP lb in sera from 3 of 106 patients with chronic immune thrombocytopenic purpura. Like the patients with quinidine-dependent platelet antibodies, however, these patients had severe thrombocytopenia, and platelet function studies were not performed.
The target 2 10,000-M antigen identified in our patient appears to be functionally related to GP lb. Evidence for this derives from three observations. First, the 210,000-Mr protein copurifies with GP lb on wheat germ affinity chromatography (unpublished observation). Second, like GP Ib, the 2 10,000-Mr protein is present in normal platelets but not on BSS platelets. This is the first demonstration of deficiency of this 2 10,000-M, glycoprotein in BSS platelets. Third, both the 2 10,000-M, protein and GP lb appear to be necessary for ristocetin-induced platelet aggregation. The specific component of GP lb to which F VIII:vWF binds has not been defined. Thus 
